FNCHQ · Finch Therapeutics Group, Inc.
$9.60
+0.00 (+0.00%)
At close · Jul 30
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$15.42M
Shares
1.61M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$107K
-87.6%
FY2023
Net Income
-$74.75M
+34.8%
FY2023
Operating Margin
-78374.77%
-64949.3pp
FY2023
Diluted EPS
-$46.59
+35.4%
FY2023
Operating Cash Flow
-$31.51M
+57.9%
FY2023
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| $0 | $107K | $861K | $18.53M | $7.72M | |
| $0 | $7.2M | $52.86M | $57.28M | $33.14M | |
| $19.69M | $26.91M | $36.19M | $21.24M | $14.01M | |
| — | $1.52M | $5.51M | $2.3M | $790K | |
| -$185K | $3.82M | $2.42M | $0 | — | |
| $19.5M | $83.97M | $116.45M | $78.52M | $47.16M | |
| -$19.5M | -$83.86M | -$115.59M | -$59.99M | -$39.44M | |
| — | -78374.77% | -13425.44% | -323.68% | -510.9% | |
| — | -$82.34M | -$110.09M | -$57.68M | -$38.65M | |
| $5.34M | $5.65M | $947K | $1.83M | $95K | |
| -$14.17M | -$78.22M | -$114.65M | -$58.16M | -$39.34M | |
| $0 | -$3.46M | $0 | $0 | $0 | |
| -$14.17M | -$74.75M | -$114.65M | -$58.16M | -$39.34M | |
| — | -69863.55% | -13315.45% | -313.84% | -509.66% | |
| USD/shares | — | -$46.59 | -$72.12 | -$44.40 | — |
| USD/shares | — | -$46.59 | -$72.12 | -$44.40 | — |
| shares | — | 1.6M | 1.59M | 1.31M | 271.5K |
| shares | — | 1.6M | 1.59M | 1.31M | 271.5K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Collaboration Revenue | $861,000 | $18,532,000 | $7,376,000 |
| Royalties Revenue from Related Party | — | — | $343,000 |